Exudative Age Related Macular Degeneration Clinical Trial
Official title:
Sirolimus in Conjunction With EYLEA® (Aflibercept) Versus EYLEA® Alone for Exudative AMD
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous intravitreal anti-vascular endothelial growth factor (antiVEGF) treatment.
This study is a single-center, masked, randomized, 36 week study, designed to evaluate the safety and treatment efficacy of intravitreal Sirolimus with adjunct EYLEA® (aflibercept) in patients with persistent edema due to neovascular AMD versus EYLEA® (aflibercept) alone. Twenty (20) patients will be randomized to receive study medication in a 1:1 ratio. Study treatment will be administered by intravitreal injections. The sham injections given in the EYLEA® alone group are needleless and they are given in order to help preserve the masking of those subjects in that treatment group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03071055 -
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
|
Phase 2 | |
| Withdrawn |
NCT04075136 -
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
|
Phase 4 | |
| Completed |
NCT00927303 -
The Spectralis-Cirrus Study
|
N/A | |
| Completed |
NCT04723160 -
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
|